Navigation Links
Einstein receives $12 million grant to develop device for preventing HIV infection

March 7, 2013 (Bronx, NY) Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded a $12 million grant from the National Institutes of Health (NIH) to develop a drug-impregnated intravaginal ring to prevent HIV infection in women.

"As we move into the fourth decade of the HIV pandemic, the disease is having its greatest impact on women, particularly in sub-Sahara Africa," said principal investigator Betsy Herold, M.D., professor of pediatrics, of microbiology & immunology, and of obstetrics & gynecology and women's health at Einstein and attending physician of pediatrics, The Children's Hospital at Montefiore.

According to UNAIDS, approximately 34 million people are living with HIV worldwide. Sub-Saharan Africa is the region most affected and accounts for 69 percent of all people living with HIV.

"To protect these women and slow the epidemic, we urgently need safe and effective prevention strategies," said Dr. Herold.

Dr. Herold and co-investigator Patrick Kiser, Ph.D., a bioengineer at the University of Utah, previously developed an intravaginal ring that delivers a potent antitretroviral drug for more than four weeks and proved highly active against HIV in laboratory studies. But learning whether the device's preclinical performance will translate into real-world effectiveness has proven difficult.

The ideal intravaginal ring must release sufficient concentrations of drug to protect women at increased risk of HIV infection. And it will contain drugs that are:

  • active in the vagina, cervix and rectum;
  • capable of both rapid and sustained drug delivery for at least one month;
  • effective against many different HIV subtypes;
  • safe;
  • inexpensive;
  • stable without needing refrigeration.

The five-year project will determine if the drug released from the ring retains anti-HIV activity in the presence of vaginal secretions. In addition, studies involving non-human primates aimed at optimizing the vaginal ring's design will be conducted at the Centers for Disease Control and Prevention.

In tests to see if two drugs work better than one, the ring will be impregnated with a second drug that inhibits HIV through a mechanism different from the first drug. A clinical study to assess the ring's safety will also be carried out; this part of the project will include U.S. women taking oral contraceptives.

The grant will also fund a clinical study to assess safety and pharmacokinetics in women on Depo Provera in Kenya (led by Jeanne Marrazzo, M.D., M.P.H., from the University of Washington, and Nelly Mugo, M.P.H., from Kenyatta National Hospital) and in U.S. women on oral contraceptive pills (led by Marla Keller, M.D., associate professor of medicine and of obstetrics & gynecology and women's health at Einstein and attending physician of medicine at Montefiore Medical Center, the University Hospital for Einstein).

"We're optimistic that the intravaginal approach to preventing HIV infection will overcome the problem of having to remember to use oral or gel products daily and will empower women to protect themselves against HIV," says Dr. Herold.

Dr. Herold has worked extensively to translate laboratory research into effective real-world preventive measures for HIV. She previously developed a laboratory test that predicts whether microbicides against HIV are safe for human use.


Contact: Kim Newman
Albert Einstein College of Medicine

Related biology news :

1. Einstein researchers receive 2 Grand Challenges Explorations grants to combat HIV and TB
2. Feinstein Institute receives $1 million grant to study impact of World Trade Center attacks on responders
3. Einstein hosts its first stem cell institute symposium
4. Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin
5. Wayne State vision restoration technology receives Notice of Allowance for US patent app
6. BU researcher receives highest honor from the National Birth Defects Prevention Network
7. Geneticist Svante Pääbo receives the $500,000 Gruber Genetics Prize
8. Artificial retina receives FDA approval
9. NTU Provost receives prestigious Imperial College fellowship joining the ranks of top UK scientists
10. Xenon Receives a Milestone Payment for Marketing Approval of Glybera in Europe
11. Brainwave "Balancing" Research Receives $1 Million Grant From The Susanne Marcus Collins Foundation, Inc.
Post Your Comments:
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology: